How similar is this cluster to the other clusters?



Genes in the cluster along with the pathways as annotated by experts

	Expert Annotation	
Treatment	Pathway	Regulation Type
MAP3K2_WT.1	Canonical MAPK	Activator
MAP3K2_WT.2	Canonical MAPK	Activator
TRAF5_WT	Canonical NFkB	Activator

Top 5 genes negatively correlated to the cluster

	Expert Annotation			
Treatment	Pathway	Regulation Type	Mean Correlation	Standard Deviation
MAP2K4_WT.2	Canonical MAPK	Activator	-0.68	0.13
AKT1S1_WT.1	TOR	Inhibitor	-0.67	0.05
PIK3R1_WT.1	Canonical PI3K/AKT	Activator	-0.65	0.07
RBPJ_WT.1	NOTCH	Activator	-0.64	0.10
AKT1S1_WT.2	TOR	Inhibitor	-0.64	0.06

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?



Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.54)	Mean ± standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling ± standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized
BRD-K78412459-001-07-0 MLS000095975 SMR000031523 AC1MMEHN BDBM64930 HMS1510I13 HMS2441M20 PubChem CID : 3237493		0.82 (in 3 replicates)	0.68 ± 0.04 Treatment | Score MAP3K2_WT.1 | 0.63 MAP3K2_WT.2 | 0.69 TRAF5_WT | 0.71	NA				Total number of assays tested in: 789. Active in the following assays: • CYP2C9 Assay (AID 777) • HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells (AID 1625) • qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP) (AID 1688) • Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound (AID 1979) • Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant C. albicans Growth in the Presence of Fluconazole (AID 2423) • Fluorescence Cell-Based Retest of C. albicans Growth in the Presence of Fluconazole (AID 2467) • Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation (AID 504834)

BRD-A50921700-001-05-5
ST50843211
AC1MG1XY
MLS001035763
HMS2980J20
STK436533
SMR000666319
PubChem CID : 2954221



NA (in 1 replicates)

0.68 ± 0.07

Treatment	Score
MAP3K2.WT.1	0.64
MAP3K2.WT.2	0.63
TRAF5.WT	0.75

NA







Total number of assays tested in: 491. Active in the following assays:

- uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase (AID 2524)
- qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)

BRD-K38340366-001-10-8
MLS001207806
MLS003876590
SMR000517221
ST50155362
ZINC04974015
AC1NY521
BDBM67642
HMS2817L13
ML280
ZINC4974015
BAS 01966230
PubChem CID : 5765514



0.88 (in 4 replicates)

0.65 ± 0.04

Treatment	Score
MAP3K2.WT.1	0.60
MAP3K2.WT.2	0.67
TRAF5.WT	0.68

NA







Total number of assays tested in: 518. Active in the following assays:

- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity (AID 2661)
- Luminescence Cell-Free Homogenous Dose Retest to Identify Inhibitors of Serine/Threonine Kinase 33 Activity (AID 2821)
- Phenotypic HTS multiplex for antifungal efflux pump inhibitors (AID 485275)
- HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS (AID 485317)
- Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)
- Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity (AID 504441)
- MLPCN Dyrk1A Kinase Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_Dose_CherryPick_Activity (AID 588345)
- HTS Assay for Peg3 Promoter Inhibitors (AID 588405)
- STK-33 Kinase Inhibition Measured in Biochemical System Using Plate Reader - 2052-02_Inhibitor_Dose_DryPowder_Activity_Set2 (AID 588480)
- uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay (AID 588493)
- STK-33 Kinase Inhibition Measured in Biochemical System Using Plate Reader - 2052-02_Inhibitor_Dose_DryPowder_Activity (AID 588632)
- Counter screen for activity against Aurora B, in dose Measured in Biochemical System Using Scintillation - 2052-06_Inhibitor_Dose_DryPowder_Activity_Set2 (AID 588756)
- uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay (AID 588850)
- Single concentration confirmation of uHTS inhibitor hits from RPN11 in a Fluorescence Polarization assay (AID 602318)
- Single concentration validation of uHTS RPN11 inhibitor hits using a Thrombin Fluorescence Polarization assay (AID 602333)
- Single concentration confirmation of uHTS hits for Peg3 Promoter Inhibitors via a luciferase reporter assay (AID 602417)
- A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296)
- A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)
- Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - HeLa Cytotoxicity (AID 624300)
- Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Primary and Confirmatory Screens (AID 624330)
- Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Counter Screen Coupled Enzyme (AID 624351)
- HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity (AID 652154)
- qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line (AID 686970)
- qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)
- qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen (AID 743279)
- Confirmed inhibitors of Serine Threonine Kinase 33, STK33 (AID 743321)

BRD-A80723361-001-06-7
MLS000120963
SMR000118340
BAS 03775057
AC1MK3FZ
BDBM62892
HMS2349A13
STK840835
PubChem CID : 3148600

0.94 (in 4 replicates)

0.65 ± 0.05

Treatment	Score
MAP3K2.WT.1	0.60
MAP3K2.WT.2	0.64
TRAF5.WT	0.71

0.579 ± 0.309

Treatment	Score
MAP3K2.WT.1	0.710
MAP3K2.WT.2	0.800
TRAF5.WT	0.226



Total number of assays tested in: 698. Active in the following assays:

- uHTS for Calpain Inhibitors (AID 1236)
- Dose Response Confirmation for Calpain Inhibitors (AID 1420)
- Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1). (AID 2098)
- Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1). (AID 2174)
- Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2). (AID 2177)
- Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2). (AID 2232)
- Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1). (AID 2233)
- Inhibitors of Cav3 T-type Calcium Channels: Primary Screen (AID 449739)
- High Throughput Screening for Cocaine Antagonists: Primary Screen (AID 449768)
- Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)
- Inhibitors of T-Type Calcium Channel (AID 489005)
- Inhibitors of T-Type Calcium Channels (AID 493021)
- Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652)
- Confirmed inhibitors of the Cav3 T-type Calcium Channel (AID 1053190)

BRD-K06654104-001-05-7
MLS000061602
SMR000069932
AC1LDTK2
AC1Q2Z21
BDBM49291
ZINC37773
HMS2456J14
STK254553
BAS 02571831
ST053202
EU-0069346
PubChem CID : 675057



0.87 (in 3 replicates)

0.64 ± 0.04

Treatment	Score
MAP3K2_WT.1	0.60
MAP3K2_WT.2	0.64
TRAF5_WT	0.68

NA







Total number of assays tested in: 766. Active in the following assays:

- qHTS Assay for Inhibitors of Firefly Luciferase (AID 411)
- Allosteric Modulators of D1 Receptors: Primary Screen (AID 641)
- qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature (AID 902)
- qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature (AID 924)
- Counter Screen for Luciferase-based Primary Inhibition Assays (AID 1006)
- High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen (AID 1239)
- Name: High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Dose Response (AID 1241)
- Primary screen for compounds that activate Alzheimer's amyloid precursor (AID 1276)
- uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells (AID 1443)
- Identification of compounds which are cytotoxic to PPC-1 cells. (AID 1447)
- qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458)
- uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1 (AID 1565)
- Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents (AID 1903)
- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- A biochemical assay using the ADP-Hunter methodology, purified TAg, and ATP to identify compounds that inhibit the ATPase activity of Tag - Counter Screen (AID 2501)
- qHTS Assay for NPC1 Promoter Activators (AID 485313)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
- qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504466)
- qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
- uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay (AID 624354)
- Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 624483)
- Single concentration confirmation of Caspase-8 TRAIL sensitizer hits in a luminesence panel assay (AID 651596)
- Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1 (AID 652010)
- Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 687014)
- High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G: A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction (AID 1117319)

BRD-K74196031-001-05-4
ST50002594
BAS 00435184
AC1LL0T8
MLS000559810
HMS2583G23
ZINC827087
STK342806
ZINC00827087
SMR000175006
PubChem CID : 1102016

0.85 (in 3 replicates)

0.64 ± 0.05

Treatment	Score
MAP3K2_WT.1	0.59
MAP3K2_WT.2	0.66
TRAF5_WT	0.68

NA

Total number of assays tested in: 629. Active in the following assays:

- Leishmania major promastigote HTS (AID 1063)
- High Throughput Imaging Assay for Hepatic Lipid Droplet Formation (AID 1656)
- MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors (AID 1813)
- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- Single concentration confirmation of HCS identification of small molecules that inhibit hepatic lipid droplet formation (AID 463183)
- High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set (AID 588499)
- uHTS identification of small molecule inhibitors of the thioesterase domain of fatty acid synthase via a fluorescence intensity assay (AID 602261)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)

BRD-A77566727-001-05-6
SMR000048526
AC1LDHDJ
MLS000084442
MLS002584781
HMS2405B07
STK788882
ST50129984
PubChem CID : 667105



0.89 (in 4 replicates)

0.64 ± 0.05

Treatment	Score
MAP3K2_WT.1	0.60
MAP3K2_WT.2	0.64
TRAF5_WT	0.69

NA







Total number of assays tested in: 775. Active in the following assays:

- CYP2C9 Assay (AID 777)
- qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)
- uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H) (AID 2012)
- uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP) (AID 2014)
- Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide. (AID 2057)
- Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL). (AID 2129)
- Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation (AID 504834)
- Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line (AID 602250)
- Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5) (AID 602281)
- Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4) (AID 624126)
- Counterscreen for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5): Luminescence-based biochemical high throughput assay to identify inhibitors of Hepatocyte nuclear factor 4 (HNF4) dimerization (AID 651674)

BRD-K75977772-001-05-9
MLS000756489
NSC205913
AC1N1LYV
ZINC5580712
ZINC05580712
NSC-205913
SMR000528759
PubChem CID : 4007404



NA (in 1 replicates)

0.64 ± 0.06

Treatment	Score
MAP3K2.WT.1	0.58
MAP3K2.WT.2	0.64
TRAF5.WT	0.70

NA







Total number of assays tested in: 565. Active in the following assays:

- MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)
- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins (AID 485364)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
- qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
- qHTS of Nrf2 Activators (AID 624171)
- Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM) (AID 652017)
- Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12) (AID 652126)
- Counterscreen for activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM): Luminescence-based cell-based high throughput screening assay to identify non-selective compounds using the VP16 reporter assay (AID 686939)

BRD-K40926874-001-06-3
T6051781
AC1OBTHD
MLS000516321
ZINC12727563
SMR000372882
PubChem CID : 6902822



0.93 (in 3 replicates)

0.64 ± 0.06

Treatment	Score
MAP3K2.WT.1	0.58
MAP3K2.WT.2	0.64
TRAF5.WT	0.70

NA







Total number of assays tested in: 636. Active in the following assays:

- qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)
- qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)
- VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)
- qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)
- uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190)
- uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay (AID 463212)
- Single concentration confirmation of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463213)
- Single concentration confirmation of small molecule inhibitors of tim23-1 yeast via a luminescent assay (AID 463218)
- HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS (AID 485317)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)

BRD-K74121099-001-05-1
MLS000089134
SMR000072827
AC1LPNXS
Ambcb7481403
MLS002541642
BDBM56185
HMS2451A15
ZINC1136310
ZINC01136310
VU0177852-6
PubChem CID : 1310230



0.84 (in 3 replicates)

0.64 ± 0.05

Treatment	Score
MAP3K2.WT.1	0.59
MAP3K2.WT.2	0.64
TRAF5.WT	0.68

NA







Total number of assays tested in: 786. Active in the following assays:

- Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells) (AID 430)
- Kallikrein 5 1536 HTS (AID 873)
- qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay (AID 995)
- Image-based Screening Assay for Inhibitors of Phagocytosis (AID 1029)
- Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5). (AID 1987)
- Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)
- Confirmatory screen for compounds that inhibit the Choline Transporter (CHT) (AID 493221)
- Dose responses of compounds that inhibit the Choline Transporter (CHT) - 5 point CRC (AID 504840)
- TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R (AID 540295)
- Dose responses of compounds that inhibit the Choline Transporter (CHT) - 10 point CRC (AID 588401)
- Counterscreen for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R): TRFRET-based cell-based high throughput assay to identify nonselective inhibitors of cAMP signaling (AID 602193)
- TRFRET-based cell-based high throughput confirmation assay for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R) (AID 602195)
- qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)
- qHTS for Inhibitors of Inflammasome Signaling: IL-1beta AlphaLISA Primary Screen (AID 743279)
- Confirmed inhibitors of the Choline Transporter (CHT) (AID 1053196)

BRD-K67411319-001-01-8
PubChem CID : 44501932

0.88 (in 3 replicates)

-0.69 ± 0.04

Treatment	Score
MAP3K2.WT.1	-0.71
MAP3K2.WT.2	-0.71
TRAF5.WT	-0.64

0.511 ± 0.297

Treatment	Score
MAP3K2.WT.1	0.278
MAP3K2.WT.2	0.846
TRAF5.WT	0.409







Total number of assays tested in: 47.

BRD-K90201499-001-01-6
PubChem CID : 54641127

NA (in 1 replicates)

-0.69 ± 0.03

Treatment	Score
MAP3K2.WT.1	-0.65
MAP3K2.WT.2	-0.71
TRAF5.WT	-0.70

NA

Total number of assays tested in: 37.

BRD-K48693155-001-01-2
PubChem CID : 54618096

0.88 (in 4 replicates)

-0.68 ± 0.05

Treatment	Score
MAP3K2.WT.1	-0.72
MAP3K2.WT.2	-0.70
TRAF5.WT	-0.63

NA

Total number of assays tested in: 37.

BRD-K15827540-001-05-0 T5250099 AC1M2QX1 MLS001010624 HMS1774C11 HMS2718E22 ZINC12531006 SMR000352827 PubChem CID : 2123280		NA (in 1 replicates)	-0.66 ± 0.02 Treatment / Score MAP3K2.WT.1 / -0.64 MAP3K2.WT.2 / -0.66 TRAF5.WT / -0.67	NA				Total number of assays tested in: 643. Active in the following assays: • Primary cell-based high throughput screening assay to measure STAT3 inhibition (AID 862) • Counter Screen for Luciferase-based Primary Inhibition Assays (AID 1006) • qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458) • qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK) (AID 1721) • Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90) (AID 1789) • qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551) • qHTS Assay for Rab9 Promoter Activators (AID 485297) • qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504466) • qHTS for Inhibitors of binding or entry into cells for Lassa Virus (AID 540256) • qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342) • Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1 (AID 652010) • qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)
BRD-K76218980-001-11-3 nikkomycin z AC1NUQ0P MLS000028371 HMS2233C10 SMR000058642 PubChem CID : 5458181		NA (in 1 replicates)	-0.65 ± 0.02 Treatment / Score MAP3K2.WT.1 / -0.65 MAP3K2.WT.2 / -0.66 TRAF5.WT / -0.63	NA				Total number of assays tested in: 698. Active in the following assays: • qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490) • Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant C. albicans Growth in the Presence of Fluconazole (AID 2423) • Fluorescence Cell-Based Retest of C. albicans Growth in the Presence of Fluconazole (AID 2467) • qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332) • qHTS of TDP-43 Inhibitors (AID 652104)
BRD-K04648846-001-02-1 MLS003129529 SMR001833975 PubChem CID : 44505579		0.72 (in 3 replicates)	-0.64 ± 0.01 Treatment / Score MAP3K2.WT.1 / -0.65 MAP3K2.WT.2 / -0.66 TRAF5.WT / -0.63	0.262 ± 0.128 Treatment / Score MAP3K2.WT.1 / 0.178 MAP3K2.WT.2 / 0.200 TRAF5.WT / 0.409				Total number of assays tested in: 222.
BRD-K39784035-001-01-6 PubChem CID : 54641194		NA (in 1 replicates)	-0.63 ± 0.04 Treatment / Score MAP3K2.WT.1 / -0.66 MAP3K2.WT.2 / -0.66 TRAF5.WT / -0.58	NA				Total number of assays tested in: 38.
BRD-K79446376-001-01-0 PubChem CID : 54641206		NA (in 1 replicates)	-0.63 ± 0.04 Treatment / Score MAP3K2.WT.1 / -0.59 MAP3K2.WT.2 / -0.67 TRAF5.WT / -0.63	NA				Total number of assays tested in: 37.
BRD-K84625203-001-01-1 PubChem CID : 54646078		NA (in 1 replicates)	-0.63 ± 0.04 Treatment / Score MAP3K2.WT.1 / -0.62 MAP3K2.WT.2 / -0.60 TRAF5.WT / -0.67	0.380 ± 0.239 Treatment / Score MAP3K2.WT.1 / 0.290 MAP3K2.WT.2 / 0.200 TRAF5.WT / 0.651				Total number of assays tested in: 40.
BRD-K18337230-001-01-1 PubChem CID : 44492103		0.61 (in 4 replicates)	-0.62 ± 0.03 Treatment / Score MAP3K2.WT.1 / -0.64 MAP3K2.WT.2 / -0.63 TRAF5.WT / -0.58	NA				Total number of assays tested in: 43.